Univariate and multivariate OS analyses of iNKT/T ratio according to baseline parameters
| Baseline parameters . | Univariate analysis* . | Multivariate analysis* . | ||
|---|---|---|---|---|
| 2-y OS, % (95% CI) . | P† . | HR (95% CI) . | P‡ . | |
| iNKT/T ratio* | ||||
| < 10−3 | 52 (35-69)§ | .002§ | 1§ | .028§ |
| ≥ 10−3 | 90 (76-100)§ | 0.19 (0.04-0.83)§ | ||
| Sex | ||||
| Male | 66 (48-83) | .546 | ||
| Female | 66 (48-84) | |||
| Age of recipient, y | ||||
| < 45 | 81 (65-98)§ | .037§ | ||
| ≥ 45 | 56 (39-74)§ | |||
| Age of donor, y | ||||
| < 35 | 72 (48-86) | .475 | ||
| ≥ 35 and < 45 | 63 (34-82) | |||
| ≥ 45 | 64 (38-81) | |||
| Hematologic disease | .573 | |||
| ALL/AML/AA/MPD | 66 (51-82) | |||
| Lymphoma/myeloma | 70 (50-90) | |||
| Disease status at transplantation | ||||
| CR | 68 (49-86) | .173 | ||
| PR or SD | 66 (48-84) | |||
| PD | 53 (4-100) | |||
| Conditioning regimen | ||||
| MAC | 72 (53-91) | .528 | ||
| RIC | 62 (46-79) | |||
| Donor | ||||
| Sibling | 80 (67-93)§ | .002§ | 1§ | .031§ |
| Unrelated (10/10 or 9/10) | 43 (21-65)§ | 2.78 (1.09-7.10)§ | ||
| Donor | ||||
| Female to male | 60 (32-88) | .495 | ||
| Other | 68 (54-82) | |||
| In vivo T depletion | ||||
| No | 78 (63-92)§ | .033§ | ||
| Yes | 51 (31-72)§ | |||
| Risk of CMV | ||||
| Low | 79 (57-100) | .128 | ||
| Intermediate | 71 (54-88) | |||
| High | 40 (12-69) | |||
| Type of graft | ||||
| BM | 59 (36-83) | .331 | ||
| PBSC | 69 (54-84) | |||
| Baseline parameters . | Univariate analysis* . | Multivariate analysis* . | ||
|---|---|---|---|---|
| 2-y OS, % (95% CI) . | P† . | HR (95% CI) . | P‡ . | |
| iNKT/T ratio* | ||||
| < 10−3 | 52 (35-69)§ | .002§ | 1§ | .028§ |
| ≥ 10−3 | 90 (76-100)§ | 0.19 (0.04-0.83)§ | ||
| Sex | ||||
| Male | 66 (48-83) | .546 | ||
| Female | 66 (48-84) | |||
| Age of recipient, y | ||||
| < 45 | 81 (65-98)§ | .037§ | ||
| ≥ 45 | 56 (39-74)§ | |||
| Age of donor, y | ||||
| < 35 | 72 (48-86) | .475 | ||
| ≥ 35 and < 45 | 63 (34-82) | |||
| ≥ 45 | 64 (38-81) | |||
| Hematologic disease | .573 | |||
| ALL/AML/AA/MPD | 66 (51-82) | |||
| Lymphoma/myeloma | 70 (50-90) | |||
| Disease status at transplantation | ||||
| CR | 68 (49-86) | .173 | ||
| PR or SD | 66 (48-84) | |||
| PD | 53 (4-100) | |||
| Conditioning regimen | ||||
| MAC | 72 (53-91) | .528 | ||
| RIC | 62 (46-79) | |||
| Donor | ||||
| Sibling | 80 (67-93)§ | .002§ | 1§ | .031§ |
| Unrelated (10/10 or 9/10) | 43 (21-65)§ | 2.78 (1.09-7.10)§ | ||
| Donor | ||||
| Female to male | 60 (32-88) | .495 | ||
| Other | 68 (54-82) | |||
| In vivo T depletion | ||||
| No | 78 (63-92)§ | .033§ | ||
| Yes | 51 (31-72)§ | |||
| Risk of CMV | ||||
| Low | 79 (57-100) | .128 | ||
| Intermediate | 71 (54-88) | |||
| High | 40 (12-69) | |||
| Type of graft | ||||
| BM | 59 (36-83) | .331 | ||
| PBSC | 69 (54-84) | |||
AA indicates aplastic anemia; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia, CI, confidence interval; CR, complete remission; HR, hazard ratio; HSC, hematopoietic stem cell; iNKT/T, invariant natural killer T/T cell; MAC, myeloablative conditioning; MDS, myelodysplasic syndrome; MPD, myeloproliferative disease; OS, overall survival; PD, progressive disease; PR, partial remission; PBSC, peripheral blood stem cells; and RIC, reduced-intensity conditioning.
Univariate and multivariate landmark analyses were conducted with a landmark time set up at day 90 when NKT reconstitution was fully determined.
Using the logrank test.
Using theCox proportional hazard ratio model. Only 1 patient died before day 90 and was therefore not included in the landmark analysis.
Statistically significant.